EFGARTIGIMOD

Clinical trials for EFGARTIGIMOD explained in plain language.

Never miss a new study

Get alerted when new EFGARTIGIMOD trials appear

Sign up with your email to follow new studies for EFGARTIGIMOD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug may offer safer option for rare Muscle-Weakening disease before surgery

Disease control Not yet recruiting

This study tests whether a newer drug, efgartigimod, works better and is safer than standard intravenous immunoglobulin (IVIG) for people with myasthenia gravis caused by a thymoma tumor. About 64 adults who need surgery to remove the tumor will receive one of the two treatments …

Matched conditions: EFGARTIGIMOD

Phase: PHASE3 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control

Last updated May 15, 2026 11:54 UTC

EFGARTIGIMOD

Get alerted when new EFGARTIGIMOD trials appear

New drug may offer safer option for rare Muscle-Weakening disease before surgery